Advances in immune⁃inflammatory mechanisms and clinical translation in coronary heart disease

DAI Anna; LIU Liyuan; HUANG Yanxin; WANG Qian; YI Xin

doi:10.14188/j.1671-8852.2025.0831

您当前的位置：

首页 >

文章列表页 >

Advances in immune⁃inflammatory mechanisms and clinical translation in coronary heart disease

更新时间：2026-11-05

- Advances in immune⁃inflammatory mechanisms and clinical translation in coronary heart disease
- Medical Journal of Wuhan University Vol. 47, Issue 10, Pages: 1421-1430(2026)
- 作者机构：
  
  武汉大学人民医院心内科/武汉大学心血管病研究所/心血管病湖北省重点实验室湖北武汉 430060
- 作者简介：
- 基金信息：
- DOI：10.14188/j.1671-8852.2025.0831
  CLC： R541
- Received：22 July 2025，
  
  Published：25 October 2026
- 稿件说明：
移动端阅览
戴安娜,刘力源,黄延鑫等.冠心病免疫炎症调控机制及临床转化的研究进展[J].武汉大学学报（医学版）,2026,47(10):1421-1430.

DAI Anna,LIU Liyuan,HUANG Yanxin,et al.Advances in immune⁃inflammatory mechanisms and clinical translation in coronary heart disease[J].Medical Journal of Wuhan University,2026,47(10):1421-1430.
戴安娜,刘力源,黄延鑫等.冠心病免疫炎症调控机制及临床转化的研究进展[J].武汉大学学报（医学版）,2026,47(10):1421-1430. DOI： 10.14188/j.1671-8852.2025.0831.

DAI Anna,LIU Liyuan,HUANG Yanxin,et al.Advances in immune⁃inflammatory mechanisms and clinical translation in coronary heart disease[J].Medical Journal of Wuhan University,2026,47(10):1421-1430. DOI： 10.14188/j.1671-8852.2025.0831.

摘要

冠状动脉粥样硬化性心脏病（CHD）是全球心血管疾病死亡的首要原因，其病理核心为动脉粥样硬化。近年来的研究揭示炎症反应贯穿动脉粥样硬化发生发展的全过程，靶向干预免疫炎症反应是未来冠心病防治的新方向。本文旨在探讨免疫炎症反应在CHD中的关键作用，通过整合代谢性炎症假说总结抗炎药物（如秋水仙碱等）、促炎因子靶向阻断（以卡纳单抗为代表）及免疫调节疗法，归纳现行的CHD免疫炎症干预方案的研究进展，并探讨其在CHD发生发展及心肌梗死后心室重构中的转化潜力。

Abstract

Coronary atherosclerotic heart disease (CHD) is the leading cause of cardiovascular mortality worldwide

with atherosclerosis as its pathological core. Recent studies have revealed that inflammatory responses are involved throughout the process of atherosclerosis development

making targeted modulation of immune⁃inflammatory reactions a promising new approach for future CHD prevention and treatment. This review aims to explore the pivotal role of immune⁃inflammatory responses in CHD. By integrating the metabolic inflammation hypothesis

we summarize current research advances in immune⁃inflammatory intervention strategies for CHD

including anti⁃inflammatory drugs (such as colchicine)

targeted blockade of pro⁃inflammatory factors (exemplified by canakinumab)

and immunomodulatory therapies. Additionally

we discuss their translational potential for the treatment of CHD progression and post⁃myocardial infarction ventricular remodeling.

关键词

Keywords

references

国家心血管病中心 , 中国心血管健康与疾病报告编写组 , 胡盛寿 , 等 . 中国心血管健康与疾病报告2023概要 [J ] . 中国循环杂志 , 2024 , 39 ( 7 ): 625 ‑ 660 .

National Center for Cardiovascular Diseases, Chinese report on cardiovascular health and diseases compilation group, HU S S, et al . Summary of China cardiovascular health and disease report 2023 [J ] . Chin Circ J , 2024 , 39 ( 7 ): 625 ‑ 660 .

TALL A R , BORNFELDT K E . Inflammasomes and atherosclerosis: A mixed picture [J ] . Circ Res , 2023 , 132 ( 11 ): 1505 ‑ 1520 .

FERNANDEZ D M , RAHMAN A H , FERNANDEZ N F , et al . Single‑cell immune landscape of human atherosclerotic plaques [J ] . Nat Med , 2019 , 25 ( 10 ): 1576 ‑ 1588 .

ROSS R , GLOMSET J A . Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis [J ] . Science , 1973 , 180 ( 4093 ): 1332 ‑ 1339 .

NEELAND I J , POIRIER P , DESPRÉS J P . Cardiovascular and metabolic heterogeneity of obesity: Clinical challenges and implications for management [J ] . Circulation , 2018 , 137 ( 13 ): 1391 ‑ 1406 .

BENTZON J F , OTSUKA F , VIRMANI R , et al . Mechanisms of plaque formation and rupture [J ] . Circ Res , 2014 , 114 ( 12 ): 1852 ‑ 1866 .

SCHELEMEI P , WAGNER E , PICARD F S R , et al . Macrophage mediators and mechanisms in cardiovascular disease [J ] . FASEB J , 2024 , 38 ( 2 ): e23424 .

DONG C . Cytokine regulation and function in T cells [J ] . Annu Rev Immunol , 2021 , 39 : 51 ‑ 76 .

HANSSON G K , LIBBY P , TABAS I . Inflammation and plaque vulnerability [J ] . J Intern Med , 2015 , 278 ( 5 ): 483 ‑ 493 .

CHISTIAKOV D A , OREKHOV A N , BOBRYSHEV Y V . Immune‑inflammatory responses in atherosclerosis: Role of an adaptive immunity mainly driven by T and B cells [J ] . Immunobiology , 2016 , 221 ( 9 ): 1014 ‑ 1033 .

XIA M , WU Q M , CHEN P F , et al . Regulatory T cell‑related gene biomarkers in the deterioration of atherosclerosis [J ] . Front Cardiovasc Med , 2021 , 8 : 661709 .

GISTERÅ A , ROBERTSON A L , ANDERSSON J , et al . Transforming growth factor‑β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin‑17‑dependent pathway [J ] . Sci Transl Med , 2013 , 5 ( 196 ): 196ra100 .

ZHANG Q , WANG L , WANG S Q , et al . Signaling pathways and targeted therapy for myocardial infarction [J ] . Signal Transduct Target Ther , 2022 , 7 ( 1 ): 78 .

GHAFOOR M , KAMAL M , NADEEM U , et al . Educational case: Myocardial infarction: Histopathology and timing of changes [J ] . Acad Pathol , 2020 , 7 : 2374289520976639 .

MATTER M A , PANENI F , LIBBY P , et al . Inflammation in acute myocardial infarction: The good, the bad and the ugly [J ] . Eur Heart J , 2024 , 45 ( 2 ): 89 ‑ 103 .

HEUSCH G , GERSH B J . The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: A continual challenge [J ] . Eur Heart J , 2017 , 38 ( 11 ): 774 ‑ 784 .

ALGOET M , JANSSENS S , HIMMELREICH U , et al . Myocardial ischemia‑reperfusion injury and the influence of inflammation [J ] . Trends Cardiovasc Med , 2023 , 33 ( 6 ): 357 ‑ 366 .

VAN HOUT G P , ARSLAN F , PASTERKAMP G , et al . Targeting danger‑associated molecular patterns after myocardial infarction [J ] . Expert Opin Ther Targets , 2016 , 20 ( 2 ): 223 ‑ 239 .

ABBATE A , SALLOUM F N , VECILE E , et al . Anakinra, a recombinant human interleukin‑1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction [J ] . Circulation , 2008 , 117 ( 20 ): 2670 ‑ 2683 .

WANDERER A A . Ischemic‑reperfusion syndromes: Biochemical and immunologic rationale for IL‑1 targeted therapy [J ] . Clin Immunol , 2008 , 128 ( 2 ): 127 ‑ 132 .

YAP J , IREI J , LOZANO‑GERONA J , et al . Macrophages in cardiac remodelling after myocardial infarction [J ] . Nat Rev Cardiol , 2023 , 20 ( 6 ): 373 ‑ 385 .

KOLOGRIVOVA I , SHTATOLKINA M , SUSLOVA T , et al . Cells of the immune system in cardiac remodeling: Main players in resolution of inflammation and repair after myocardial infarction [J ] . Front Immunol , 2021 , 12 : 664457 .

GARLAPATI V , LUO Q , POSMA J , et al . Macrophage‑expressed coagulation factor Ⅶ promotes adverse cardiac remodeling [J ] . Circ Res , 2024 , 135 ( 8 ): 841 ‑ 855 .

RIDKER P M , HENNEKENS C H , BURING J E , et al . C‑reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women [J ] . N Engl J Med , 2000 , 342 ( 12 ): 836 ‑ 843 .

RIDKER P M , RIFAI N , STAMPFER M J , et al . Plasma concentration of interleukin‑6 and the risk of future myocardial infarction among apparently healthy men [J ] . Circulation , 2000 , 101 ( 15 ): 1767 ‑ 1772 .

RIDKER P M , DANIELSON E , FONSECA F A , et al . Reduction in C‑reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial [J ] . Lancet , 2009 , 373 ( 9670 ): 1175 ‑ 1182 .

BUSTOS C , HERNÁNDEZ‑PRESA M A , ORTEGO M , et al . HMG‑CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis [J ] . J Am Coll Cardiol , 1998 , 32 ( 7 ): 2057 ‑ 2064 .

ORTEGO M , BUSTOS C , HERNÁNDEZ‑PRESA M A , et al . Atorvastatin reduces NF‑kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells [J ] . Atherosclerosis , 1999 , 147 ( 2 ): 253 ‑ 261 .

LU L , LIU H , PENG J H , et al . Regulations of the key mediators in inflammation and atherosclerosis by aspirin in human macrophages [J ] . Lipids Health Dis , 2010 , 9 : 16 .

LI X H , ZHANG G X , CAO X . The function and regulation of platelet P2Y12 receptor [J ] . Cardiovasc Drugs Ther , 2023 , 37 ( 1 ): 199 ‑ 216 .

WANG Y T , TIKELLIS C , THOMAS M C , et al . Angiotensin converting enzyme 2 and atherosclerosis [J ] . Atherosclerosis , 2013 , 226 ( 1 ): 3 ‑ 8 .

DEROISSART J , PORSCH F , KOLLER T , et al . Anti‑inflammatory and immunomodulatory therapies in atherosclerosis [J ] . Handb Exp Pharmacol , 2022 , 270 : 359 ‑ 404 .

MACLEOD C , HADOKE P W F , NIXON M . Glucocorticoids: Fuelling the fire of atherosclerosis or therapeutic extinguishers? [J ] . Int J Mol Sci , 2021 , 22 ( 14 ): 7622 .

GARCÍA R A , SEARCH D J , LUPISELLA J A , et al . 11β‑hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE ⁻/⁻ mice [J ] . PLoS One , 2013 , 8 ( 2 ): e53192 .

KIPARI T , HADOKE P W F , IQBAL J , et al . 11β‑hydroxysteroid dehydrogenase type 1 deficiency in bone marrow‑derived cells reduces atherosclerosis [J ] . FASEB J , 2013 , 27 ( 4 ): 1519 ‑ 1531 .

IQBAL J , MACDONALD L J , LOW L , et al . Contribution of endogenous glucocorticoids and their intravascular metabolism by 11β‑HSDs to postangioplasty neointimal proliferation in mice [J ] . Endocrinology , 2012 , 153 ( 12 ): 5896 ‑ 5905 .

GOODWIN J E , ZHANG X B , ROTLLAN N , et al . Endothelial glucocorticoid receptor suppresses atherogenesis: Brief report [J ] . Arterioscler Thromb Vasc Biol , 2015 , 35 ( 4 ): 779 ‑ 782 .

PREUSCH M R , RATTAZZI M , ALBRECHT C , et al . Critical role of macrophages in glucocorticoid driven vascular calcification in a mouse‑model of atherosclerosis [J ] . Arterioscler Thromb Vasc Biol , 2008 , 28 ( 12 ): 2158 ‑ 2164 .

JÜNI P , NARTEY L , REICHENBACH S , et al . Risk of cardiovascular events and rofecoxib: Cumulative meta‑analysis [J ] . Lancet , 2004 , 364 ( 9450 ): 2021 ‑ 2029 .

BALLY M , DENDUKURI N , RICH B , et al . Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta‑analysis of individual patient data [J ] . BMJ , 2017 , 357 : j1909 .

MISAWA T , TAKAHAMA M , KOZAKI T , et al . Microtubule‑driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome [J ] . Nat Immunol , 2013 , 14 ( 5 ): 454 ‑ 460 .

SCHWARZ N , FERNANDO S , CHEN Y C , et al . Colchicine exerts anti‑atherosclerotic and‑plaque‑stabilizing effects targeting foam cell formation [J ] . FASEB J , 2023 , 37 ( 4 ): e22846 .

TARDIF J C , KOUZ S , WATERS D D , et al . Efficacy and safety of low‑dose colchicine after myocardial infarction [J ] . N Engl J Med , 2019 , 381 ( 26 ): 2497 ‑ 2505 .

NIDORF S M , EIKELOOM J W , BUDGEON C A , et al . Low⁃dose colchicine for secondary prevention of cardiovascular disease [J ] . J Am Coll Cardiol , 2013 , 61 ( 4 ): 404 ⁃ 410 .

NIDORF S M , FIOLET A T L , MOSTERD A , et al . Colchicine in patients with chronic coronary disease [J ] . N Engl J Med , 2020 , 383 ( 19 ): 1838 ‑ 1847 .

VAIDYA K , ARNOTT C , MARTÍNEZ G J , et al . Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: A CT coronary angiography study [J ] . JACC Cardiovasc Imaging , 2018 , 11 ( 2 Pt 2 ): 305 ‑ 316 .

VISSEREN F L J , MACH F , SMULDERS Y M , et al . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice [J ] . Eur Heart J , 2021 , 42 ( 34 ): 3227 ‑ 3337 .

VIRANI S S , NEWBY L K , ARNOLD S V , et al . 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: A report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines [J ] . Circulation , 2023 , 148 ( 9 ): e9 ‑ e119 .

MEWTON N , ROUBILLE F , BRESSON D , et al . Effect of colchicine on myocardial injury in acute myocardial infarction [J ] . Circulation , 2021 , 144 ( 11 ): 859 ‑ 869 .

TONG D C , BLOOM J E , QUINN S , et al . Colchicine in patients with acute coronary syndrome: two‑year follow‑up of the Australian COPS randomized clinical trial [J ] . Circulation , 2021 , 144 ( 19 ): 1584 ‑ 1586 .

VRINTS C , ANDREOTTI F , KOSKINAS K C , et al . 2024 ESC Guidelines for the management of chronic coronary syndromes [J ] . Eur Heart J , 2024 , 45 ( 36 ): 3415 ‑ 3537 .

JUNG M , DODSWORTH M , THUM T . Inflammatory cells and their non‑coding RNAs as targets for treating myocardial infarction [J ] . Basic Res Cardiol , 2018 , 114 ( 1 ): 4 .

RYABOV V , GOMBOZHAPOVA A , ROGOVSKAYA Y , et al . Cardiac CD68 + and stabilin‑1 + macrophages in wound healing following myocardial infarction: From experiment to clinic [J ] . Immunobiology , 2018 , 223 ( 4/5 ): 413 ‑ 421 .

XU G R , ZHANG C , YANG H X , et al . Modified Citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin‑3 and TLR4/MyD88/NF‑κB signaling pathway [J ] . Biomed Pharmacother , 2020 , 126 : 110071 .

SUN J H , YANG H X , YAO T T , et al . Gentianella acuta prevents acute myocardial infarction induced by isoproterenol in rats via inhibition of galectin‑3/TLR4/MyD88/NF‑кB inflammatory signalling [J ] . Inflammopharmacology , 2021 , 29 ( 1 ): 205 ‑ 219 .

RAMIREZ‑CARRACEDO R , TESORO L , HERNANDEZ I , et al . Targeting TLR4 with ApTOLL improves heart function in response to coronary ischemia reperfusion in pigs undergoing acute myocardial infarction [J ] . Biomolecules , 2020 , 10 ( 8 ): 1167 .

SORAYA H , CLANACHAN A S , RAMESHRAD M , et al . Chronic treatment with metformin suppresses toll‑like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction [J ] . Eur J Pharmacol , 2014 , 737 : 77 ‑ 84 .

SU Q , LV X W , SUN Y H , et al . Role of TLR4/MyD88/NF‑κB signaling pathway in coronary microembolization‑induced myocardial injury prevented and treated with nicorandil [J ] . Biomed Pharmacother , 2018 , 106 : 776 ‑ 784 .

WANG F Y , GONG Y , CHEN T , et al . Maresin1 ameliorates ventricular remodelling and arrhythmia in mice models of myocardial infarction via NRF2/HO‑1 and TLR4/NF‑κB signalling [J ] . Int Immunopharmacol , 2022 , 113 : 109369 .

KAWAGUCHI M , TAKAHASHI M , HATA T , et al . Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury [J ] . Circulation , 2011 , 123 ( 6 ): 594 ‑ 604 .

SANDANGER Ø , RANHEIM T , VINGE L E , et al . The NLRP3 inflammasome is up‑regulated in cardiac fibroblasts and mediates myocardial ischaemia‑reperfusion injury [J ] . Cardiovasc Res , 2013 , 99 ( 1 ): 164 ‑ 174 .

VAN HOUT G P J , BOSCH L , ELLENBROEK G H J M , et al . The selective NLRP3‑inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction [J ] . Eur Heart J , 2017 , 38 ( 11 ): 828 ‑ 836 .

TAN H P , SONG Y N , CHEN J , et al . Platelet‑like fusogenic liposome‑mediated targeting delivery of miR‑21 improves myocardial remodeling by reprogramming macrophages post myocardial ischemia‑reperfusion injury [J ] . Adv Sci , 2021 , 8 ( 15 ): 2100787 .

JIANG J J , GU X P , WANG H F , et al . Resveratrol improves cardiac function and left ventricular fibrosis after myocardial infarction in rats by inhibiting NLRP3 inflammasome activity and the TGF‑β1/SMAD2 signaling pathway [J ] . PeerJ , 2021 , 9 : e11501 .

QIU H L , LIU W , LAN T H , et al . Salvianolate reduces atrial fibrillation through suppressing atrial interstitial fibrosis by inhibiting TGF‑β1/Smad2/3 and TXNIP/NLRP3 inflammasome signaling pathways in post‑MI rats [J ] . Phytomedicine , 2018 , 51 : 255 ‑ 265 .

GAO R F , LI X , XIANG H Y , et al . The covalent NLRP3‑inflammasome inhibitor Oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice [J ] . Int Immunopharmacol , 2021 , 90 : 107133 .

ZHAO Z H , ZHANG X M , SUN T N , et al . Prognostic value of systemic immune‑inflammation index in CAD patients: Systematic review and meta‑analyses [J ] . Eur J Clin Investig , 2024 , 54 ( 2 ): e14100 .

URBANOWICZ T , MICHALAK M , KOMOSA A , et al . Predictive value of systemic inflammatory response index (SIRI) for complex coronary artery disease occurrence in patients presenting with angina equivalent symptoms [J ] . Cardiol J , 2024 , 31 ( 4 ): 583 ‑ 595 .

MURAT B , MURAT S , OZGEYIK M , et al . Comparison of pan‑immune‑inflammation value with other inflammation markers of long‑term survival after ST‑segment elevation myocardial infarction [J ] . Eur J Clin Investig , 2023 , 53 ( 1 ): e13872 .

RIDKER P M , EVERETT B M , THUREN T , et al . Antiinflammatory therapy with canakinumab for atherosclerotic disease [J ] . N Engl J Med , 2017 , 377 ( 12 ): 1119 ‑ 1131 .

KLEVELAND O , KUNSZT G , BRATLIE M , et al . Effect of a single dose of the interleukin‑6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non‑ST‑elevation myocardial infarction: A double‑blind, randomized, placebo‑controlled phase 2 trial [J ] . Eur Heart J , 2016 , 37 ( 30 ): 2406 ‑ 2413 .

BROCH K , ANSTENSRUD A K , WOXHOLT S , et al . Randomized trial of interleukin‑6 receptor inhibition in patients with acute ST‑segment elevation myocardial infarction [J ] . J Am Coll Cardiol , 2021 , 77 ( 15 ): 1845 ‑ 1855 .

RIDKER P M , DEVALARAJA M , BAERES F M M , et al . IL‑6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): A double‑blind, randomised, placebo‑controlled, phase 2 trial [J ] . Lancet , 2021 , 397 ( 10289 ): 2060 ‑ 2069 .

LAHOUTE C , HERBIN O , MALLAT Z , et al . Adaptive immunity in atherosclerosis: Mechanisms and future therapeutic targets [J ] . Nat Rev Cardiol , 2011 , 8 ( 6 ): 348 ‑ 358 .

LI J , GUASCH‑FERRÉ M , CHUNG W , et al . The Mediterranean diet, plasma metabolome, and cardiovascular disease risk [J ] . Eur Heart J , 2020 , 41 ( 28 ): 2645 ‑ 2656 .

GEORGE E S , GEORGOUSOPOULOU E N , MELLOR D D , et al . Exploring the path of Mediterranean diet, non‑alcoholic fatty liver disease (NAFLD) and inflammation towards 10‑year cardiovascular disease (CVD) risk: The ATTICA study 10‑year follow‑up (2002‑2012) [J ] . Nutrients , 2022 , 14 ( 12 ): 2367 .

HU L H , HU B X , ZHANG L , et al . Role of gut microbiota and metabolomics in the lipid‑lowering efficacy of statins among Chinese patients with coronary heart disease and hypercholesterolemia [J ] . Front Cell Infect Microbiol , 2024 , 14 : 1408581 .

MA J W , LI K . Systemic immune‑inflammation index is associated with coronary heart disease: A cross‑sectional study of NHANES 2009‑2018 [J ] . Front Cardiovasc Med , 2023 , 10 : 1199433 .

LIU Y H , YE T , CHEN L , et al . Systemic immune‑inflammation index predicts the severity of coronary stenosis in patients with coronary heart disease [J ] . Coron Artery Dis , 2021 , 32 ( 8 ): 715 ‑ 720 .

CANDEMIR M , KIZILTUNÇ E , NURKOÇ S , et al . Relationship between systemic immune‑inflammation index (SII) and the severity of stable coronary artery disease [J ] . Angiology , 2021 , 72 ( 6 ): 575 ‑ 581 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of laparoscopic modified non⁃mesh iliopubic ligament suspension in the treatment of pelvic organ prolapse

The mechanism and preventive therapeutic value of nuclear factor erythroid 2⁃related factor 2 in ischemic stroke

Effects of Hederagenin on cardiac hypertrophy and fibrosis induced by pressure overload in mice

Comparison of the effects of propofol and ciprofol on cardiovascular autonomic nervous system during anesthesia induction period

Repetitive transcranial magnetic stimulation improves synaptic ultrastructure in a mouse model of Alzheimer's disease

Related Author

HUANG Yanxin WANG Qian

YI Xin

易欣

Related Institution

No data

AI问答

⁰